Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
10-KAnnual report [Section 13 and 15(d), not S-K Item 405]2023-09-292023-06-30
8-KCurrent report2023-09-252023-09-25
8-KCurrent report2023-09-252023-09-22
8-KCurrent report2023-09-082023-09-07
4Statement of changes in beneficial ownership of securities2023-08-312023-08-31
8-KCurrent report2023-07-242023-07-21
8-KCurrent report2023-07-202023-07-20
8-KCurrent report2023-06-222023-06-22
8-KCurrent report2023-06-012023-06-01
8-KCurrent report2023-05-252023-05-24
8-KCurrent report2023-05-192023-03-18
4Statement of changes in beneficial ownership of securities2023-05-162023-05-16
4Statement of changes in beneficial ownership of securities2023-05-162023-05-16
8-KCurrent report2023-05-162023-05-15
4Statement of changes in beneficial ownership of securities2023-05-162023-05-16
10-QQuarterly report [Sections 13 or 15(d)]2023-05-152023-03-31
8-KCurrent report2023-03-282023-03-28
8-KCurrent report2023-03-14
4Statement of changes in beneficial ownership of securities 2023-03-09
4Statement of changes in beneficial ownership of securities 2023-03-09
4Statement of changes in beneficial ownership of securities 2023-03-09
8-KCurrent report, items 7.01 and 9.01 Acc-no: 0001213900-23-018211 (34 Act)2023-03-07
8-KCurrent report2023-02-212023-02-17
10-QQuarterly report [Sections 13 or 15(d)]2023-02-172022-12-31
SC 13GStatement of acquisition of beneficial ownership by individuals2023-02-14
NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB2023-02-102022-12-31
8-KCurrent report2023-01-102023-01-10
4Statement of changes in beneficial ownership of securities2022-12-192022-12-16
4Statement of changes in beneficial ownership of securities2022-12-192022-12-16
4Statement of changes in beneficial ownership of securities2022-12-192022-12-16
  • « Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*